Numerous Taxotere lawsuits have been filed in recent years. The FDA approved Taxotere for use in 1996. In 2009, the last year before Sanofi dropped its patent protection, the drug earned $3 billion for its manufacturer. Plaintiffs in Taxotere lawsuits claim that the drug causes permanent hair loss, alopecia, also that the manufacturer failed to warn them of the threat. While temporary baldness is a frequent side effect of chemotherapy treatment, permanent hair loss is not common.
Plaintiffs claim that if the producer had effectively warned of the threat they’d have selected treatment with Taxol. While Taxol is arguably more effective than Taxotere is necessitates a greater number of remedies.